PEN-866 safety, efficacy and pharmacokinetics is being investigated in an ongoing Phase 1/2a clinical trial in patients with advanced solid tumors.
PEN-866 is a miniature drug conjugate that selectively binds to the intracellular target Heat Shock Protein 90 (HSP90) and is linked to a topoisomerase 1 inhibitor (SN-38), a potent anti-cancer payload. PEN-866 accumulates and is retained in tumors and, by way of a sustained release of SN-38, causes prolonged DNA damage and tumor regressions in multiple patient-derived and other xenograft tumor models. PEN-866 is the first miniature drug conjugate from Tarveda’s HSP90 binding conjugate platform.
PEN-221 safety, efficacy and pharmacokinetics is currently being investigated in an ongoing Phase 2a clinical trial in patients with neuroendocrine cancers, including GI neuroendocrine and small cell lung cancer.
PEN-221 is a miniature drug conjugate designed to rapidly penetrate deep into solid tumors where it is highly selective for the somatostatin receptor 2 (SSTR2) and accumulates its potent DM1 payload. SSTR2 is overexpressed on the surface of cancer cells in patients with neuroendocrine cancers.